Illumina must unwind its $7.1 billion acquisition of cancer-test developer Grail, the European Union’s competition watchdog said.

Illumina must unwind its $7.1 billion acquisition of cancer-test developer Grail, the European Union’s competition watchdog said. https://ift.tt/azyJgUZ